UBS AM
NRIX icon

UBS AM’s Nurix Therapeutics NRIX Stock Holding History

UBS AM’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.28M Sell
135,104
-22,246
-14% -$379K ﹤0.01% 1826
2026
Q1 		$2.44M Sell
157,350
-11,493
-7% -$191K ﹤0.01% 1942
2025
Q4 		$3.2M Buy
168,843
+70,698
+72% +$1.02M ﹤0.01% 1683
2025
Q3 		$907K Sell
98,145
-133,910
-58% -$1.39M ﹤0.01% 2039
2025
Q2 		$2.64M Buy
232,055
+72,525
+45% +$784K ﹤0.01% 2021
2025
Q1 		$1.9M Buy
159,530
+12,817
+9% +$214K ﹤0.01% 2018
2024
Q4 		$2.76M Buy
146,713
+18,189
+14% +$417K ﹤0.01% 1886
2024
Q3 		$2.89M Sell
128,524
-147
-0.1% -$3.33K ﹤0.01% 1843
2024
Q2 		$2.69M Buy
+128,671
New +$2M ﹤0.01% 1836
2023
Q4 		– Sell
-240,608
Closed -$1.89M – 2582
2023
Q3 		$1.89M Sell
240,608
-6,103
-2% -$55.7K ﹤0.01% 1659
2023
Q2 		$2.19M Hold
246,711
– – ﹤0.01% 1606
2023
Q1 		$2.19M Buy
246,711
+1,215
+0.5% +$12.7K ﹤0.01% 1606
2022
Q4 		$2.7M Buy
245,496
+14,904
+6% +$180K ﹤0.01% 1404
2022
Q3 		$3M Sell
230,592
-13,713
-6% -$217K ﹤0.01% 1390
2022
Q2 		$3.1M Sell
244,305
-8,967
-4% -$102K ﹤0.01% 1421
2022
Q1 		$3.55M Sell
253,272
-25,618
-9% -$455K ﹤0.01% 1504
2021
Q4 		$8.07M Sell
278,890
-7,209
-3% -$219K ﹤0.01% 1204
2021
Q3 		$8.57M Buy
286,099
+219
+0.1% +$6.76K ﹤0.01% 1147
2021
Q2 		$7.58M Buy
+285,880
New +$8.39M ﹤0.01% 1212

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS AM's NRIX Position: Q2 2026 in Review

UBS AM reduced its Nurix Therapeutics (NRIX) stake by 14% in Q2 2026, selling an estimated $379K and leaving 135,104 shares worth $3.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1826.

UBS AM first reported a position in NRIX in Q2 2021 and has held it in 19 quarters since. The position peaked at $8.57M in Q3 2021. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • UBS AM held 135,104 shares of Nurix Therapeutics worth $3.28M as of Q2 2026.
  • UBS AM sold 22,246 Nurix Therapeutics shares in Q2 2026, an estimated $379K.
  • Nurix Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1826 holding.
  • UBS AM first reported a position in Nurix Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • UBS AM's Nurix Therapeutics position peaked at $8.57M in Q3 2021.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.